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E-mail address: julian.cambronero@wright.edu (J.Janus kinase 3 (JAK3) is a non-receptor tyrosine kinase vital to the regulation of T-cells. We report
that JAK3 is a mediator of interleukin-8 (IL-8) stimulation of a different class of hematopoietic rel-
evant cells: human neutrophils. IL-8 induced a time- and concentration-dependent activation of
JAK3 activity in neutrophils and differentiated HL-60 leukemic cells. JAK3 was more robustly acti-
vated by IL-8 than other kinases: p70S6K, mTOR, MAPK or PKC. JAK3 silencing severely inhibited
IL-8-mediated chemotaxis. Thus, IL-8 stimulates chemotaxis through a mechanism mediated by
JAK3. Further, JAK3 activity and chemotaxis were inhibited by the ﬂavonoid apigenin (40,5,7-trihydr-
oxyﬂavone) at 5 nM IC50. These new ﬁndings lay the basis for understanding the molecular mech-
anism of cell migration as it relates to neutrophil-mediated chronic inﬂammatory processes.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction ducers and STAT proteins and negatively regulate the JH1 domain.The non-receptor tyrosine kinase Janus kinase 3 (JAK3) is vital
to the regulation of T-cell signaling, lymphoid development and se-
vere combined immunodeﬁciency (SCID) [1,2]. JAK3 is exclusively
expressed in myeloid and lymphoid cell lines and in hematopoietic
tissues like the thymus, spleen, bone marrow and fetal liver [3,4].
Mice lacking a catalytically intact JAK3 exhibit defects in B lym-
phocyte maturation and T lymphocyte activation [5,6]. Thymo-
cytes and bone marrow progenitor cells from Jak 3/ mice have
decreased chemotactic responses to the chemokines CXCL12 and
CCL25 [7]. Additionally, leukemic cells require an active JAK3 en-
zyme in order to be killed by small molecule tyrosine kinase inhib-
itors [8]. Similar to other JAK family kinases, JAK3 contains seven
JAK homology domains (JH) [9]. The JH1 domain is the putative
kinase domain whose activity is regulated by tyrosine phosphory-
lation at Y980 and Y981. The pseudokinase JH2 domain is
catalytically inactive and is rumored to interact with signal trans-chemical Societies. Published by E
kin-8; dHL-60, differentiated
Biochemistry and Molecular
640 Colonel Glenn Highway,
30.
Gomez-Cambronero).The N-terminal JH6 and JH7 domains are implicated in binding to
the gamma chain (cc) receptor and mutation at Y100 eliminates
this interaction, which ultimately inhibits JAK3 activation. Addi-
tionally, JAK3 is implicated in signaling pathways of several cyto-
kines that are involved in allergic airway disease/pulmonary
inﬂammation (IL-2, -4, -7, -9 and -15) via phosphorylation of
downstream STAT proteins [10–12], which directly links growth
factor receptors to gene transcription.
Interleukin-8 (IL-8) is involved in several human diseases
including inﬂammation, wound repair, angiogenesis, chronic
obstructive pulmonary disease (COPD), atherosclerosis and can-
cer metastasis, and its primary target is induction of chemotaxis
in granulocytic neutrophils and lymphocytes [13–18]. Besides
inducing chemotaxis, IL-8 also induces changes in cytosolic cal-
cium, neutrophil lipid metabolism, exocytosis and recruits neu-
trophils by binding and activating speciﬁc receptors, termed
Cys-X-Cys-R (CXCR)-1 and -2 [19–23]. IL-8 mediated cell migra-
tion begins with polarization of neutrophils in the direction of
the inﬂammation site followed by chemotaxis towards host- or
pathogen-derived chemoattractants [24]. Neutrophils from stage
I COPD patients have normal responses to IL-8, but in the more
advanced stages of disease (II–IV), neutrophils showed markedly
reduced spontaneous migration and chemotaxis in response to
IL-8 [25].lsevier B.V. All rights reserved.
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stimulated human polymorphonuclear neutrophils (PMN). Here,
we have determined the effect of IL-8-mediated activation of
JAK3 in human PMN and in the neutrophil-like differentiated HL-
60 cells (dHL-60) and found that JAK3 is robustly involved in IL-
8-iduced chemotaxis. Additionally, we are also demonstrating a
potent effect of the ﬂavonoid apigenin in neutrophil and HL-60 cell
motility.
2. Materials and methods
2.1. Chemicals
Human IL-8 was from R&D Systems (Minneapolis, MN). Myelin
basic protein (MBP) to be used as the MAPK substrate and S6 Ki-
nase (RsK2) substrate peptide 2 (KKRNRTLTV) were from Millipore
(Temecula, CA). The PKC substrate (QKRPSQRSKYL) and the JAK3
peptide substrate ‘‘Jak3tide’’ (GGEEEEYFELVKKKK) were from Up-
state (Lake Placid, NY). Apigenin was from Sigma (St. Louis, MO).
2.2. Isolation of peripheral blood neutrophils and HL-60 differentiation
(dHL-60)
Neutrophils were isolated from peripheral blood of human do-
nors who had signed an IRB-approved consent form similar to
Ref. [26] and were estimated to be >95% pure. HL-60 cells were
maintained in Iscove’s DMEM containing 40% fetal calf serum,
2 mM L-glutamine and penicillin/streptomycin. Cell density was
maintained between 1 and 2  106 cells/ml. HL-60s were differen-
tiated (dHL-60) for 4 days using 1.75% (v/v) DMSO in the complete
growth media in order to achieve the expression of the neutrophil-
ic phenotype. Both neutrophils and dHL-60 cells were ultimately
each resuspended in HBSS at a concentration 1.5  106 cells/ml
for use in chemotaxis assays or 1  107 cells/ml for use in both
PLD and kinase assays.
2.3. dsRNA Transfection of dHL-60 cells
Twenty-four hours after induction of differentiation, HL-60 cells
were transfected with 300 nM dsRNA’s using nucleofection per the
manufacturer’s protocol (Amaxa, Gaithersburg, MD). Fresh DMSO
to 1.75% (v/v) was added to the media post-nucleofection, and cells
were cultured for an additional 72 h period. For JAK silencing, we
used a ‘‘Selected validated’’ dsRNA from Applied Biosystems (Fos-
ter City, CA) that targeted exon 19; sense sequence: 50-GUA-
UCGUGGUGUCAGCUAUtt-30. For PKC silencing, we used a dsRNA
from Santa Cruz Biotechnology (Santa Cruz, CA) that targeted ﬁve
different exons speciﬁc for the PKC isoforms a, b, d, l and i. The se-
quences target the following ﬁve regions: ACCAAGCAGAAGACCA-
ACA; CACUGCACCGACUUCAUCU; UCAGUCCAUCAACAAGCAA; GGG
AUGUGCAAAGAGAACA and CAGAGAAGCACGUGUUUGA. A nega-
tive control for all silencing was 100 nM siRNA ‘‘Neg-siRNA#2’’,
purchased from Applied Biosystems. This control siRNA is a
19 bp scrambled sequence with 30 dT overhangs (sequence not dis-
closed by Applied Biosystems) certiﬁed not to have signiﬁcant
homology to any known gene sequences frommouse, rat or human
and causes no signiﬁcant changes in gene expression of transfected
cells after 48 h at the same concentration as the dsRNA in test.2.4. Chemotaxis assays
Neutrophils or dHL-60s were resuspended at a concentration
1.5  106 cells/ml in chemotaxis buffer (HBSS + 0.5% bovine serum
albumin). Two hundred microliters cells were applied to the upper
chamber of 5 lm Transwells (24-well format) with a 6.5 mm diam-eter membrane. IL-8 (20 nM) in 500 ll of chemotaxis buffer was
placed in the lower wells. Reactions were incubated for 1 h at
37 C in a 5% CO2 cell culture incubator. Results were quantiﬁed
in triplicate as number of cells migrated per insert.
2.5. Kinase assays
Approximately 5  106 human neutrophils or dHL-60 cells were
incubated with 20 nM IL-8 for 14 min at 37 C. After stimulation,
cells were sedimented, washed and ﬁnally lysed via sonication in
20 ll SLB containing protease inhibitors. Each lysate was incubated
in the presence of the following ﬁnal concentration of each:
8.25 mM HEPES, pH 7.5, 18.75 mM MgCl2, 1.25 mM EGTA,
18.75 lM Na Orthovanadate, 3.125 lM p-nitrophenylphosphate
(PNPP), 0.625 lCi [c-32P]-ATP, 40 lM cold ATP and the relevant
kinase substrate to yield a 40 ll total kinase reaction volume. Cell
lysates were immunoprecipitated with an antibody at 1 lg/ll
intended to be used for the kinase assay (i.e., with anti-JAK3 for
JAK3 kinase assay or with anti-PKC for a PKC kinase assay). For
the speciﬁc isoforms of PKC, each sample was incubated with
10 lg of anti-myc-agarose, anti-PKCa-agarose, anti-PKCb-agarose
or anti-PKCd-agarose at 4 C for 2 h using a tube rotisserie. Each
immunoprecipitate was washed and resuspended into 2  30 ll
volumes of SLB and used in the kinase assays as listed above using
no peptide substrate or the PKC peptide substrate only. To further
account for speciﬁcity, each kinase reaction contained a relevant,
speciﬁc kinase substrate. The concentration of those are as follows:
no peptide negative control, 500 lM MBP as the MAPK substrate,
62.5 lM S6 Kinase substrate peptide-2, 10 lM active MAPK for
mTOR, 62.5 lM PKC substrate and 42 lM JAK3tide substrate. All
kinase reactions were incubated at 30 C for 20 min. Reactions
were stopped by spotting 20 ll reactions onto 2  2.5 cm2 pieces
of P81 Whatman ﬁlter paper for duplicate determinations. After
washing all samples in ﬁlters were counted in a Beckman LS
6000TA liquid scintillation counter using the [32P] protocol for
1 min each. Results were quantiﬁed as DPMs and expressed in
terms of -fold activation.
2.6. Phosphorylation of H2B
Immunoprecipitations with anti-PKCa antibodies were con-
ducted similar to [27]. After immunoprecipitation, kinase assay
was performed by incubating anti-PKCa-agarose for 1 h at 37 C
in the presence of 20 ll kinase assay buffer (25 mM HEPES, pH
7.3, 10 mM MnCl2, 1 mM MgCl2, 1 mM DTT, 0.5 mM cold ATP and
5 lCi [c-32P] ATP). To each reaction, 5 lg of histone H2B was added
as exogenous substrate. Reactions were stopped by the addition of
10 ll 5 Laemmli buffer. Samples were boiled for 5 min and
loaded onto a SDS–polyacrylamide gel.
2.7. Conditions for inhibition with apigenin
Approximately 5  106 human neutrophils or dHL-60 cells were
incubated with the appropriate concentration of apigenin (in 1000-
concentrated stock) for 20 min in a 37 C water bath with vigorous
shaking. After incubation with the inhibitor, cells were either
mock-treated or treated with 20 nM IL-8 for 14 min at 37 C. After
stimulation, cells were sedimented and washed and lysed via son-
ication in 200 ll SLB containing protease inhibitors.
2.8. Statistical analysis
Data are presented as the mean + S.E. The difference between
means was assessed by the single factor analysis of variance (AN-
OVA) test. Probability of P < 0.05 was considered to indicate a sig-
niﬁcant difference.
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3.1. IL-8 stimulates JAK3 activity of human PMN and leukemic cells
IL-8 stimulates the activity of JAK3 in human neutrophils in a
time (Fig. 1A) and concentration dependent (Fig. 1B) fashion. Max-
imal phosphorylation of the JAK3 peptide substrate occurred at 5–
7 min when using 20 nM IL-8 (Fig. 1A). Additionally, between 1
and 10 nM IL-8 provided optimal JAK3 phosphorylation at 7 min
of time (Fig. 1B). The combination of immunoprecipitation with
anti-JAK3 antibodies and the use of the JAK3 speciﬁc synthetic pep-
tide substrate, GGEEEEYFELVKKKK, made it possible for us to
ascertain that the isoform being conserved is indeed JAK3 (over
JAK1 or JAK2). JAK3tide as an exclusive peptide substrate for
JAK3 has been utilized by other authors [28], as it is phosphory-
lated by JAK3 at Tyr-7 and not by any other JAK family kinase.
We next compared the effect of IL-8 on JAK3 kinase activity be-
tween freshly isolated neutrophils and differentiated HL-60 that
express the neutrophilic phenotype. We wanted to do this because
subsequent experiments used molecular biology approaches
(silencing with dsRNA and incubation for several days) that areJA
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Fig. 1. IL-8 stimulates JAK3 activity of human neutrophils and differentiated HL-60
immunoprecipitated with speciﬁc anti-JAK3 antibodies and JAK3 kinase reactions perform
in neutrophils. (C) Effect of anti-IL-8R antibodies preincubated with 20 nM IL-8 prior tonot possible to evaluate with short-lived neutrophils. As indicated
in Fig. 1C, IL-8 was able to stimulate the activity of JAK3 in neutr-
ophilic dHL-60 albeit at a lower extent than that seen in fresh neu-
trophils, but still in a signiﬁcant way over controls. When IL-8 was
preincubated with antibodies to the IL-8 receptor (IL-8R) and sub-
sequently utilized in the stimulation of cells, JAK3 phosphorylation
was completely abrogated in both neutrophils and dHL-60s
(Fig. 1C), indicating that the stimulation effect is mediated by the
receptor of IL-8 speciﬁcally. Thus, we conclude that we are docu-
menting a novel ﬁnding that JAK3 is present in neutrophils and
can be speciﬁcally activated in vitro by IL-8 in both human neutro-
phils and differentiated leukemic dHL-60 cells.
3.2. IL-8-stimulated chemotaxis is mediated by JAK3
As known, IL-8 is a potent chemoattractant for neutrophils.
Fig. 2A shows that it is also a chemoattractant for neutrophilic
dHL-60 leukemic cells. The number of cells that migrated in re-
sponse to 20 nM IL-8 increased in proportion to increasing time
of migration (open triangles) compared to the non-stimulated cells
(open circles). As a negative control, Fig. 2A also shows IL-8-dHL-60s
+) anti-IL-8R
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Fig. 2. IL-8-stimulated dHL-60 cell chemotaxis is mediated by JAK3. (A) Time
course of IL-8-stimulated chemotaxis. Number of migrated cells/Transwell insert
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chambers of Transwell inserts. Results are the mean ± S.E. from three ﬁelds of view
at 20 magniﬁcation. Control, untreated cells (open circles), cells treated with
20 nM IL-8 only (open triangles). (B) Effect of silencing JAK3 with dsRNA for 4 days
on dHL-60 cell chemotaxis. Si-Neg is a scrambled dsRNA.
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Fig. 3. Apigenin is a powerful inhibitor of both JAK3 activity and chemotaxis. (A
insert) Schematic drawing of apigenin structure. Neutrophils or dHL-60 cells were
treated with increasing apigenin for 20 min at 37 C followed by 20 nM IL-8
stimulation for 10 min at 37 C. (A) Effect of apigenin on JAK3 activity of neutrophils
(open circles) or dHL-60 cells (ﬁlled circles). (B) Time course of IL-8-stimulated
dHL-60 cell chemotaxis in the presence (ﬁlled triangles) or absence (open triangles)
of apigenin. (C) Concentration dependent response of apigenin concentrations and
effect on neutrophil chemotaxis. Unstimulated neutrophils (open circles), neutro-
phils stimulated with 20 nM IL-8 (ﬁlled circles).
162 K.M. Henkels et al. / FEBS Letters 585 (2011) 159–166independent cell migration, chemokinesis, was detected in these
cells but to a very limited and small extent (only about 20% of
IL-8 stimulated cells at maximal time) (circles). Importantly, this
effect was dependent on JAK3, as silencing with siRNA speciﬁc
for JAK3 inhibited both basal chemokinesis by 30% (Fig. 2B, left
group of bars) and IL-8 activated chemotaxis by 50% (Fig. 2B,
right group of bars). This serves to indicate that IL-8-induced
chemotaxis has a strong component that relies on JAK3 for intra-
cellular signaling.
3.3. JAK3 activity is inhibited by apigenin
Next, we endeavored to further manipulate the IL-8-stimulated
kinase activity with a small molecule inhibitor compound that
could inhibit tyrosine kinases. We chose to use 40,5,7-trihydroxyf-
lavone (apigenin, Fig. 3A, inset) a plant polyphenol, ﬂavonoid agly-
cone derived from green leafy vegetables [29–32]. Apigenin
mediates inhibition of tyrosine kinase activities via interaction
with the ATP-binding site of the speciﬁc kinase, which results in
suppression of oncogene expression [27,33–40]. It also inhibits cell
proliferation by arresting the cell cycle at G2/M phase [41–44].
Using either neutrophils or dHL-60 cells, we show the positive
effect of 20 nM IL-8 stimulation on JAK3 (Fig. 3A) activity in theabsence of apigenin. Following incubation with increasing
concentrationsof apigenin, JAK3phosphorylationactivitydrastically
decreased to near baseline in both cell models. IC50 apigenin
concentrations for JAK3 were 1.3 nM for neutrophils and 1.1 nM for
dHL-60 cells. Although an IC50 concentration of apigenin for JAK3
has not been reported to date by any other group, the IC50
K.M. Henkels et al. / FEBS Letters 585 (2011) 159–166 163concentration of apigenin for immunopuriﬁedphosphatidylinositol-
3-kinase (PI3K) from human blood platelets has been determined to
be much higher at 12 lM [36].
After measuring the effect of apigenin on JAK3 in vitro, we
found that apigenin could inhibit IL-8-mediated dHL-60 cell che-
motaxis in a time dependent manner, as evidenced in Fig. 3B.
The number of cells that migrated in response to 20 nM IL-8 in-
creased in proportion to increasing time of migration (open trian-
gles). However, in the presence of 50 nM apigenin, IL-8-mediatedB
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Si-Control is a scrambled dsRNA.cell migration was reduced by >70%, speciﬁcally at early times
(10–30 min of chemotaxis) (ﬁlled triangles).
Next, we performed a concentration dependent experiment to
ascertain the IC50 of apigenin in vitro during chemotaxis
(Fig. 3C). Using increasing concentrations of apigenin up to 1 lM,
we determined the IC50 concentration of apigenin to be 20 nM
for human neutrophils cells (Fig. 3C) in response to <20 nM IL-8.
The decrease in chemotaxis was drastic and signiﬁcant. Addition-
ally, the IC50 value for neutrophils was in the subnanomolar rangeNeutrophils
I.P. PKC
δβ1α
I.P. PKC
dHL-60s
δβ1α
IgG PKCα
H2B
PKCα
0 3 7 100
Apigenin Incubation (min)
]
]
In Vitro
Kinase Assay
W.B.
Control si-PKC si-Neg
20 nM IL-8
Control Control
es total PKC activity of human neutrophils and differentiated HL-60 cells. Cells were
C kinase reactions performed as in Section 2. (B) Neutrophil and dHL-60 cell lysates
KCb1- or a-PKCd-agarose and used in the PKC kinase assay. (C) Effect of apigenin on
ell lysates were immunoprecipitated with anti-PKCa antibodies or IgG control and
inase reactions were resolved by SDS–PAGE, Western blot transferred and products
apigenin on PKCa phosphorylation of H2B (top panel). The same membrane was
panel). (E) Effect of silencing PKC with dsRNA for 4 days on dHL-60 cell chemotaxis.
164 K.M. Henkels et al. / FEBS Letters 585 (2011) 159–166indicating the extreme potency of apigenin to inhibit cell migra-
tory functions. We also determined the IC50 concentration of apige-
nin to be 3.5 nM for dHL-60 cells in response to 20 nM IL-8 (data
not shown). We report the effect of subnanomolar concentrations
of apigenin on cell migration, while other groups have reported
similar negative effects on cell migration assays but at 1000-fold
more apigenin (submicromolar range) [54,55]. These data suggest
apigenin is a powerful inhibitor of chemoattractant-mediated cell
migrations.
3.4. IL-8 stimulates other kinases: PKCa and PKCd, albeit at a lower
extent than JAK3
We have shown here for the ﬁrst time that IL-8 stimulates JAK3
kinase activity in human neutrophils and the neutrophil-like hu-
man promyelocytic dHL-60 cells. Additionally, we wanted to deter-
mine how speciﬁc the effect of IL-8 stimulation was on JAK3. We
performed similar kinase assays as those utilized for JAK3 (immu-
noprecipitation using speciﬁc kinase substrates as indicated in Sec-
tion 2) and found that other kinases were activated by IL-8 in
neutrophils; all but PKC exerted a lower extent of activation than
JAK3. Further, we calculated the neutrophilic IC50 concentrations
for apigenin inhibition for other kinases as follows: MAPK
(1 lM), S6K (14 lM), mTOR (1 lM). All are 1–2 orders of magni-
tude greater than that of JAK3 as reported here.
Out of the four kinases, both the enhancing effect of IL-8 med-
iated by PKC and the inhibition by apigenin were somewhat close
to that observed with JAK3, and we further explored PKC. Fig. 4A
shows that the effect of IL-8 is in the range of what we have ob-
served for JAK3 (Fig. 1C) albeit slightly lower. We next investigated
which speciﬁc PKC subunits were involved in IL-8 signaling in hu-
man PMN and leukemic cells. Cell lysates were prepared and
immunoprecipitated using antibodies speciﬁc for a-myc (a nega-
tive control reaction) and three different subunits of PKC: PKCa,
PKCb1 and PKCd. As indicated in Fig. 4B, PKCa and PKCd were de-
tected in both IL-8-stimulated neutrophils and dHL-60 cells. PKCd
and PKCa were about 3.5-fold greater in neutrophils and 1.5-fold
greater in dHL-60 cells when each was compared to their respec-
tive negative controls, respectively. Peak activity of each kinase
was achieved at 10–14 min of incubation time (data not shown).
In general, PKCa and PKCd activities were more robustly measured
in human neutrophils when compared to dHL-60 cells. PKCb1 ki-
nase activity was equal to or fell below that of the negative control
a-myc immunoprecipitates and, therefore, was not readily quanti-
ﬁable in either cell line using our experimental design.
PKC phosphorylation activity decreased as well in the presence
of apigenin but not to the same extent as JAK3 activity (Fig. 4C).
IC50 apigenin concentrations for total PKC activity were 15 nM
for neutrophils (open circles) and 10-fold greater (200 nM) for
dHL-60 cells (ﬁlled circles). Previously, it has been reported by
Huang et al. that the IC50 concentration of apigenin for PKC is
10 lM in murine embryonic ﬁbroblasts [37]. The data presented
here indicate that neutrophils are more sensitive to apigenin than
ﬁbroblasts [36,37]. As PKCa was the PKC isoform that was acti-
vated to the greatest extent in both neutrophils and dHL-60 cells,
we chose to determine the level of PKCa activity of an actual
downstream protein substrate and not a synthetic peptide sub-
strate (histone-2B, H2B). As shown in Fig. 4D, PKCa was able to
phosphorylate the protein substrate H2B when stimulated with
IL-8. When in the presence of 50 nM apigenin, markedly less phos-
phorylation of H2B by PKCa was evident. After 10 min of incuba-
tion with apigenin, H2B phosphorylation by PKCa decreased by
more than 50% when compared to the PKCa loading control.
Lastly, the PKC-mediated component of PKC activation does not
seem to play as important a role in chemotaxis as does JAK3, as
silencing with dsRNA speciﬁc for PKC had a marginal effect on che-motaxis (Fig. 4E). Silencing with siRNA speciﬁc for PKC inhibited
basal chemokinesis by only 15% (Fig. 4E, left group of bars) and
IL-8 activated chemotaxis by 20% (Fig. 4E, right group of bars).
4. Discussion
The non-receptor tyrosine kinase JAK3 is vital to the regulation
of T-cell signaling, lymphoid development and severe combined
immunodeﬁciency (SCID), which contributes to it being considered
a potential and worthwhile pharmacological target. Recently, JAK3
has speciﬁcally been implicated in myeloid cell development, as
mutations to JAK3 have been found in acute megakaroblastic leu-
kemia [45]. Thymocytes and bone marrow progenitor cells from
Jak 3/mice have decreased chemotactic responses to the chemo-
kines CXCL12 and CCL25 [7]. The N-terminal FERM and possibly
the SH2-like domains of JAK proteins regulate catalytic activity
and/or are involved in binding to and association with relevant
cytokine receptors and are considered vital to the initial steps in-
volved in cytokine-mediated signaling [9,46,47]. The conversion
of the extracellular binding signal following binding to the receptor
of interest into a cascade of tyrosine kinase activity is mediated
predominantly by JAK proteins. JAK3 is speciﬁcally implicated in
signaling pathways of several interleukin cytokines that are in-
volved in allergic airway disease/pulmonary inﬂammation via
phosphorylation of downstream STAT proteins [10–12].
It has been shown that airway epithelial cells secrete various
chemokines, cytokines, extracellular matrix proteins and lipid
mediators, one of which is IL-8 that is already known to attract
neutrophils and other hematopoietic cells to the site of inﬂamma-
tion [48–50]. IL-8 is involved in several human diseases including
inﬂammation, and its primary target is induction of chemotaxis
in granulocytic neutrophils and leukocytes, which are appropriate
cell motility models for inﬂammation, tumor migration or wound
healing. JAK3 has been found to have a pivotal role in mast cell-
mediated bacterial clearance and neutrophil recruitment via regu-
lation of TNF from mast cells [51].
Unlike G-CSF which cannot activate JAK3 in human neutrophils
[52], we have shown for the ﬁrst time that JAK3 can be correlated
to human neutrophilic function in a time and concentration depen-
dent manner and via the IL-8 signal transduction pathway, which
implicates a role for JAK3 in IL-8-mediated inﬂammatory processes
and cancer. Upon further determination, both PKCa and PKCdwere
found to be IL-8-activated to a greater extent in neutrophilic
lysates than in leukemic cell lysates following immunoprecipita-
tion with antibodies speciﬁc to either kinase. JAK3 is more robustly
activated in neutrophils by IL-8 than other kinases like PKC, MAPK,
mTOR or p70S6K, which further implicates a JAK3 mechanism in
IL-8-stimulated chemotaxis.
We have shown here JAK3 and PKCa phosphorylation activities
in both neutrophils and leukemic cells following IL-8 stimulation
are negatively affected by apigenin action. Additionally, we have
associated the presence of nanomolar concentrations of apigenin
to negative effects on random and chemoattractant-stimulated cell
migration of neutrophils and leukocytes in a time and concentration
dependent manner. It has been determined that submicromolar
concentrations of apigenin suppressed by a factor of approximately
9-fold the release or production of proinﬂammatory cytokines,
including IL-8, in human monocytes [53]. Apigenin has been found
to severely hinder cell migratory processes, particularly adhesion,
chemotaxis, invasion and metastasis in ovarian, breast, melanoma
lung, cervical and prostate cancers [54–59]. Conventional wisdom
suggests that apigenin is a pleiotropic effector that affects prote-
ase-dependent invasiveness and associated processes, proliferation
of tumor cells and actin cytoskeleton organization, which exerts an
anti-tumorigenic effect in vivo via inhibition of tumor cell penetra-
tion into healthy tissue.
K.M. Henkels et al. / FEBS Letters 585 (2011) 159–166 165In conclusion, our results provide documentation of the novel
effect of IL-8-stimulated JAK3 activation in human neutrophils
and leukemia. We have documented a previously deﬁned molecu-
lar mechanism relevant to inﬂammation and cancer that also un-
iquely regulates JAK3. We have demonstrated that apigenin
interferes with IL-8-mediated chemotaxis of human neutrophils
and leukocytes that can be correlated to suppression of certain
tyrosine kinases, namely JAK3, PKCa and PKCd.
Additionally, we have been able to correlate a role for JAK3 in
leukemic cell migration as transfection of JAK3 siRNA into dHL-
60 cells severely inhibited chemotactic cells in response to IL-8.
As apigenin effectively binds to JAK3 and suppresses this kinase
moiety, information presented here could be used to design new
chemotherapeutic strategies against IL-8-mediated inﬂammation
and leukemia, potentially including use of the IL-8 receptor.
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